V3 seroreactivity and sequence variation: Tracking the emergence of V3 genotypic variation in HIV-1-infected patients

AIDS

Volumn 10, Issue 2, 1996, Pages 121-129

  Michael, Nelson L ^a,d   Davis, Kim E ^b   Loomis Price, Lawrence D ^b   VanCott, Thomas C ^a   Burke, Donald S ^a   Redfield, Robert R ^c   Birx, Deborah L ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Antibodies; DNA sequencing; Genetics; HIV 1; Polymerase chain reaction; V3 loop

Indexed keywords

GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS DNA;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEROCONVERSION; VIRUS GENOME; VIRUS IMMUNITY;

EID: 0029671077     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199602000-00001     Document Type: Article

References (54)

1. Bolognesi DP: The immune response to HIV: implications for vaccine development. Semin Immunol 1993, 5:203-214.
2. La Rosa GJ, Davide JP, Weinhold K, et al.: Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990, 249:932-935.
3. Berger EA, Sisler JR, Earl PL: Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release. J Virol 1992, 66:6208-6212.
4. Bergeron L, Sullivan N, Sodroski J: Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus. J Virol 1992, 66:2389-2397.
5. Chesebro B, Wehrly K, Nishio J, Perryman S: Macrophagetropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol 1992, 66:6547-6554.
6. de Jong JJ, Goudsmit J, Keulen W, et al.: Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol 1992, 66:757-765.
7. de Jong JJ, de Ronde A, Keulen W, Tersmette M, Goudsmit J: Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992, 66:6777-6780.
8. Fouchier RA, Groenink M, Kootstra NA, et al.: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992, 66:3183-3187.
9. Freed EO, Risser R: Identification of conserved residues in the human immunodeficiency virus type 1 principal neutralizing determinant that are involved in fusion. AIDS Res Hum Retroviruses 1991, 7:807-811.
10. Freed EO, Myers DJ, Risser R: Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain. J Virol 1991, 65:190-194.
11. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991, 253:71-74.
12. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR: Identification of envelope V3 loop as the major determinant of CD4 neutralizing sensitivity of HIV-1. Science 1992, 257:535-537.
13. Milich L, Margolin B, Swanstrom R: V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol 1993, 67:5623-5634.
14. Shioda T, Levy JA, Cheng-Mayer C: Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1992, 89:9434-9438.
15. Berman PW, Gregory TJ, Riddle L, et al.: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990, 345:622-625.
16. Fultz PN, Nara P, Barre SF, et al.: Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992, 256:1687-1690.
17. Korber BTM, MacInnes K, Smith RF, Myers G: Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol 1994, 68:6730-6744.
18. Mulder-Kampinga GA, Kuiken C, Dekker J, Scherpbier HJ, Boer K, Goudsmit J: Genomic human immunodeficiency virus type 1 RNA variation in mother and child following intra-uterine virus transmission. J Gen Virol 1993, 74:1747-1756.
19. Ou CY, Ciesielski CA, Myers G, et al.: Molecular epidemiology of HIV transmission in a dental practice. Science 1992, 256:1165-1171.
20. Scarlatti G, Leitner T, Hodara V, et al.: Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1. AIDS 1993, 7 (suppl 2):S45-S48.
21. Wolfs TF, Zwart G, Bakker M, Goudsmit J: HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology 1992, 189:103-110.
22. Wolinsky SM, Wike CM, Korber BT, et al.: Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992, 255:1134-1137.
23. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Leigh Brown AJ, Simmonds P: Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993, 67:3345-3356.
24. Zhu T, Mo H, Wang N, et al.: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993, 261:1179-1181.
25. Pang S, Shlesinger Y, Daar ES, Moudgil T, Ho DD, Chen ISY: Rapid generation of sequence variation during primary HIV-1 infection. AIDS 1992, 6:453-460.
26. Redfield RR, Birx DL, Ketter N, et al.: A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991, 324:1677-1684.
27. Redfield RR, Wright DC, Tramont EC: The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med 1986, 314:131-132.
28. Michael NL, Chang G, Ehrenberg PK, Vahey MT, Redfield RR: HIV-1 proviral genotypes from the peripheral blood mononuclear cells of an infected patient are differentially represented in expressed sequences. J Acquir Immune Defic Syndr 1993, 6:1073-1085.
29. Nei M, Gojobori T: Simple methods estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 1986, 3:418-426.
30. Li WH, Wu CI, Luo CC: A new method for estimating synonymous and nonsynonymous rates of nucleotide substitution considering the relative likelihood of nucleotide and codon changes. Mol Biol Evol 1985, 2:150-174.
31. Loomis LL, Deal CD, Kersey KS, Burke DS, Redfield RR, Birx DL: Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160. J Acquir Immune Defic Syndr 1995, 10:13-26.
32. Myers G, Korber B, Wain-Hobson S, Smith RF, Pavlakis GN (Eds): Human Retroviruses and AIDS. Los Alamos: Los Alamos National Laboratory; 1993.
33. Museing MA, Smith DH, Cabradilla CD, Benton CV, Lasky LA, Capon DJ: Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature 1985, 313:450-458.
34. Hill RE, Hastie ND: Accelerated evolution in the reactive centre regions of serine protease inhibitors. Nature 1987, 326:96-99.
35. Hughes AL, Nei M: Nucleotide substitution at major histocompatibility complex class II loci: evidence for overdominant selection. Proc Natl Acad Sci USA 1989, 86:958-962.
36. Hughes AL, Nei M: Pattern of nucleotide substitution at major histocompatibiliy complex class I loci reveals overdominant selection. Nature 1988, 335:167-170.
37. VanCott TC, Bethke FR, Polonis VR, et al.: Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol 1994, 153:449-459.
38. Moore JP: The reactivities of HIV-1+ human sera with solid-phase V3 loop peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules. AIDS Res Hum Retroviruses 1993, 9:209-219.
39. Holmback K, Kusk P, Hulgaard EF, Bugge TH, Scheibel E, Lindhardt BO: Autologous antibody response against the principal neutralizing domain of human immunodeficiency virus type 1 isolated from infected humans. J Virol 1993, 67:1612-1619.
40. Arendrup M, Sonnerborg A, Svennerholm B, et al.: Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J Gen Virol 1993, 74:855-863.
41. Delassus S, Cheynier R, Wain-Hobson S: Evolution of human immunodeficiency virus type 1 nef and long terminal repeat sequences over 4 years in vivo and in vitro. J Virol 1991, 65:225-231.
42. Holmes EC, Zhang LQ, Simmonds P, Ludlam CA, Leigh Brown AJ: Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient. Proc Natl Acad Sci USA 1992, 89:4835-4839.
43. Meyerhans A, Cheynier R, Albert J, et al.: Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 1989, 58:901-910.
44. Simmonds P, Zhang LQ, McOmish F, Balfe P, Ludlam CA, Leigh Brown AJ: Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis. J Virol 1991, 65:6266-6276.
45. Wolfs TF, de Jong JJ, Van den Berg H, Tijnagel JM, Krone WJ, Goudsmit J: Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. Proc Natl Acad Sci USA 1990, 87:9938-9942.
46. Zwart G, Wolfs TF, Valk M, Van der Hoek L, Kuiken CL, Goudsmit J: Characterization of the specificity of the human antibody response to the V3 neutralization domain of HIV-1. AIDS Res Hum Retroviruses 1992, 8:1897-1908.
47. Robertson DL, Hahn B, McCutchan F, Sharp P: Recombination in HIV-1. Nature 1995, 374:124-126.
48. Pedroza Martins L, Chenciner N, Wain-Hobson S: Complex intrapatient sequence variation in the V1 and V2 hypervariable regions of the HIV-1 gp 120 envelope sequence. Virology 1992, 191:837-845.
49. Lamers SL, Sleasman JW, She JX, et al.: Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo. J Virol 1993, 67:3951-3960.
50. Lamers SL, Sleasman JW, She JX, et al.: Persistence of multiple maternal genotypes of human immunodeficiency virus type I in infants infected by vertical transmission. J Clin Invest 1994, 93:380-390.
51. Delwart EL, Sheppard HW, Walker BD, Goudsmit J, Mullins JI: Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol 1994, 68:6672-6683.
52. Goodenow M, Huet T, Saurin W, Kwok S, Sninsky J, Wain-Hobson S: HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr 1989, 2:344-352.
53. McNearney T, Hornickova Z, Markham R, et al.: Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci USA 1992, 89:10247-10251.
54. Korber B, Wolinsky S, Haynes B, et al.: HIV-1 intrapatient sequence diversity in the immunogenic V3 region. AIDS Res Hum Retroviruses 1992, 8:1461-1465.